ASP0113 (Vical Incorporated)

ASP0113 (also known as TransVax or VCL-CB01) is a bivalent DNA plasmid vaccine developed to prevent cytomegalovirus (CMV) infection and disease in immunocompromised patients, specifically those undergoing hematopoietic cell transplant (HCT) or solid organ transplant (SOT). The vaccine consists of two distinct plasmids: one encoding the CMV envelope glycoprotein B (gB) to induce neutralizing antibodies, and another encoding the 65 kDa phosphoprotein (pp65) to stimulate cell-mediated immune responses. These plasmids are formulated with a CRL1005 poloxamer and benzalkonium chloride delivery system designed to enhance plasmid uptake and expression. Originally developed by Vical and later licensed to Astellas Pharma, ASP0113 reached Phase 3 clinical trials (the HELIOS study). However, in 2018, Astellas announced that the vaccine failed to meet its primary and secondary endpoints in HCT recipients, leading to the discontinuation of its development.

Brand names

TransVax

Other names

CMV DNA vaccineVical CMV vaccineVCL-CB01 vaccineVCL-CB-01 vaccineVCL-CB 01 vaccine